These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 35572927)

  • 1. Can Old Animals Reveal New Targets? The Aging and Degenerating Brain as a New Precision Medicine Opportunity for Epilepsy.
    Del Pozo A; Lehmann L; Knox KM; Barker-Haliski M
    Front Neurol; 2022; 13():833624. PubMed ID: 35572927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery.
    Del Pozo A; Barker-Haliski M
    Exp Neurol; 2023 Feb; 360():114288. PubMed ID: 36471511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's Disease and Epilepsy: A Perspective on the Opportunities for Overlapping Therapeutic Innovation.
    Lehmann L; Lo A; Knox KM; Barker-Haliski M
    Neurochem Res; 2021 Aug; 46(8):1895-1912. PubMed ID: 33929683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus Recommendations.
    Smith MC; Klein P; Krauss GL; Rashid S; Seiden LG; Stern JM; Rosenfeld WE
    Neurol Ther; 2022 Dec; 11(4):1705-1720. PubMed ID: 36057761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-seizure medications for Lennox-Gastaut syndrome.
    Brigo F; Jones K; Eltze C; Matricardi S
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD003277. PubMed ID: 33825230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening.
    Barker-Haliski M; Steve White H
    Neuropharmacology; 2020 May; 167():107750. PubMed ID: 31469995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with psychogenic nonepileptic seizures and suspected epilepsy: An antiseizure medication reduction study.
    Tavakoli Yaraki P; Paredes-Aragon E; Joe Yu Y; AlKhateeb M; Mirsattari SM
    Epilepsy Behav; 2023 Apr; 141():109116. PubMed ID: 36807990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Lattanzi S; Trinka E; Russo E; Del Giovane C; Matricardi S; Meletti S; Striano P; Damavandi PT; Silvestrini M; Brigo F
    Drugs; 2023 Oct; 83(15):1409-1424. PubMed ID: 37695433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the FDA-approved cannabidiol on the development and persistence of temporal lobe epilepsy and complex focal onset seizures.
    Reddy DS; Mbilinyi RH; Ramakrishnan S
    Exp Neurol; 2023 Jan; 359():114240. PubMed ID: 36216124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The Basis of Medication Therapy for Epilepsy].
    Hanaya R
    No Shinkei Geka; 2023 Jan; 51(1):95-104. PubMed ID: 36682754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug-resistant epilepsy in England.
    Raspin C; Shankar R; Barion F; Pollit V; Murphy J; Sawyer L; Danielson V
    J Med Econ; 2021; 24(1):1037-1051. PubMed ID: 34348576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tackling seizures in patients with Alzheimer's disease.
    Tombini M; Boscarino M; Di Lazzaro V
    Expert Rev Neurother; 2023; 23(12):1131-1145. PubMed ID: 37946507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shift from older- to newer-generation antiseizure medications in people with acute ischemic stroke in Australia: A population-based study.
    Kim SJ; Wood S; Marquina C; Foster E; Bell JS; Ilomäki J
    Epilepsia Open; 2023 Dec; 8(4):1413-1424. PubMed ID: 37574594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure to use new breakthrough treatments for epilepsy.
    Klein P; Krauss GL; Steinhoff BJ; Devinsky O; Sperling MR
    Epilepsia; 2023 Jun; 64(6):1458-1465. PubMed ID: 36855241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug resistant epilepsy in the United States.
    Raspin C; Faught E; Armand J; Barion F; Pollit V; Murphy J; Danielson V
    J Med Econ; 2023; 26(1):189-199. PubMed ID: 36691763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiseizure Medications in Alzheimer's Disease from Preclinical to Clinical Evidence.
    Bosco F; Guarnieri L; Rania V; Palma E; Citraro R; Corasaniti MT; Leo A; De Sarro G
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of normal Alzheimer's disease-associated Presenilin 2 function alters antiseizure medicine potency and tolerability in the 6-Hz focal seizure model.
    Lehmann LM; Barker-Haliski M
    Front Neurol; 2023; 14():1223472. PubMed ID: 37592944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
    Talwar A; Estes E; Aparasu R; Reddy DS
    Exp Neurol; 2023 Jan; 359():114238. PubMed ID: 36206805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal Models of Drug-Resistant Epilepsy as Tools for Deciphering the Cellular and Molecular Mechanisms of Pharmacoresistance and Discovering More Effective Treatments.
    Löscher W; White HS
    Cells; 2023 Apr; 12(9):. PubMed ID: 37174633
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.